24-5860
L-脯氨酸
SAJ special grade, ≥99.0%
别名:
( S )-吡咯烷-2-羧酸
等级
SAJ special grade
方案
≥99.0%
表单
solid
存货情况
available only in Japan
dilution
(for analytical testing)
mp
228 °C (dec.) (lit.)
SMILES字符串
OC(=O)[C@@H]1CCCN1
InChI
1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1
InChI key
ONIBWKKTOPOVIA-BYPYZUCNSA-N
正在寻找类似产品? 访问 产品对比指南
储存分类代码
13 - Non Combustible Solids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Marie Couturier et al.
The Journal of biological chemistry, 288(20), 14624-14635 (2013-04-06)
The microbial deconstruction of the plant cell wall is a key biological process that is of increasing importance with the development of a sustainable biofuel industry. The glycoside hydrolase families GH5 (PaMan5A) and GH26 (PaMan26A) endo-β-1,4-mannanases from the coprophilic ascomycete
Salvatore Petta et al.
Hepatology (Baltimore, Md.), 59(5), 1692-1705 (2014-04-03)
We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype.
Michael P Manns et al.
Gastroenterology, 147(2), 366-376 (2014-04-15)
MK-5172 is an inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A protease; MK-5172 is taken once daily and has a higher potency and barrier to resistance than licensed protease inhibitors. We investigated the efficacy and tolerability of MK-5172
R A Wevers et al.
Clinical chemistry, 40(7 Pt 1), 1245-1250 (1994-07-01)
Although spin-echo techniques are often used to obtain 1H-NMR spectra of serum or plasma samples, they do not provide reliable quantitative analyses of metabolites. We present a standardized procedure, optimized for sensitivity, for using single-pulse 1H-NMR spectroscopy to analyze deproteinized
David Saadoun et al.
Annals of the rheumatic diseases, 73(5), 831-837 (2013-04-23)
The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination. To analyse the safety and efficacy of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持